Research programme: H2stem - Promethera Biosciences

Drug Profile

Research programme: H2stem - Promethera Biosciences

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Promethera Biosciences
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency
  • Research Fibrosis; Non-alcoholic steatohepatitis

Most Recent Events

  • 09 Jan 2017 Promethera Biosciences and LifeLiver enter into a strategic alliance to jointly develop H2Stem in South Korea
  • 26 Oct 2016 Early research in Fibrosis in Belgium (unspecified route) (Promethera Biosciences pipeline, October 2016)
  • 26 Oct 2016 Early research in Non-alcoholic steatohepatitis in Belgium (unspecified route) (Promethera Biosciences pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top